
1. antimicrob agents chemother. 2012 jul;56(7):3615-9. doi: 10.1128/aac.06350-11.
epub 2012 apr 16.

pfmdr1 amplification related increased plasmodium falciparum vitro
sensitivity bisquinoline piperaquine.

veiga mi(1), ferreira pe, malmberg m, jörnhagen l, björkman a, nosten f, gil jp.

author information: 
(1)malaria research lab, department medicine, karolinska institutet,
stockholm, sweden. maria.isabel.veiga@gmail.com

the 4-aminoquinoline bisquinoline piperaquine important partner drug one
of presently recommended artemisinin combination therapies. recent clinical
trials confirmed high efficacy combination dihydroartemisinin.
resistance piperaquine alone has, however, documented. amplification in
copy number plasmodium falciparum multidrug resistance locus chromosome
5, containing pfmdr1 gene, shown confer resistance to
structurally unrelated antimalarials. determination 50%
inhibitory concentrations (ic(50)s) ic(90)s piperaquine chloroquine
in set 46 adapted p. falciparum cultures originating thai-burmese
border, characterized regions around pfmdr1 gene identified a
significant association presence pfmdr1 duplications enhanced 
sensitivity piperaquine (p = 0.005 ic(50) p = 0.002 ic(90)) and
chloroquine, reaching statistical significance ic(90)s (p = 0.026). these
results substantiate potential importance pfmdr1 copy number
amplifications efficacy combination therapy
piperaquine-dihydroartemisinin. supports rational use 4-aminoquinolines
and artemisinin-based compounds, independently select mutually
incompatible combinations mutations.

doi: 10.1128/aac.06350-11 
pmcid: pmc3393437
pmid: 22508315  [indexed medline]

